Dr. Stephen Oroszlan obtained his Ph.D. in Pharmacology from Georgetown University. After his postdoctoral training at the National Cancer Institute (NCI) from 1961 to 1963, he conducted biochemical research on retroviruses at the Albert Einstein Medical Center, George Washington University School of Medicine, and Flow Laboratories. In 1976, he returned to NCI, and served as Director of the Molecular Virology and Carcinogenesis Laboratory, ABL-Basic Research Program, from 1983 to 1995. Dr. Oroszlan was appointed Scientist Emeritus in 1995, and since 1999 he has been affiliated with the HIV Drug Resistance Program (renamed the HIV Dynamics and Replication Program in 2015). His studies have provided invaluable information on the biosynthesis of retroviral enzymes and structural proteins. He has published more than 250 papers and was named one of the most highly cited researchers in microbiology by the Institute for Scientific Information. Dr. Oroszlan has been awarded three U.S. patents and one European patent on HIV protease and one U.S. patent on chloroquine as an inhibitor of infectious HIV production. His numerous honors include the award of a Doctor Honoris Causa Degree from the University of Debrecen Medical School in 1993, election to the Hungarian Academy of Sciences as a Foreign Associate in 1994, a Retroviral Retrospective Symposium to Honor Dr. Stephen Oroszlan held at Hood College in 1994, and the Mór Kaposi Research Foundation Award in 2000.
Last modified: 20 October 2018